MARKET

PTCT

PTCT

Ptc Therapeutics
NASDAQ
84.43
-0.08
-0.09%
After Hours: 84.43 0 0.00% 16:35 06/26 EDT
OPEN
84.69
PREV CLOSE
84.51
HIGH
85.83
LOW
83.25
VOLUME
3.90M
TURNOVER
--
52 WEEK HIGH
87.50
52 WEEK LOW
43.18
MARKET CAP
7.00B
P/E (TTM)
-36.5435
1D
5D
1M
3M
1Y
5Y
1D
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?
NASDAQ · 22h ago
PTC Therapeutics (PTCT) Launches Sephience After Strong Early Sales And $500 Million Raise
Simply Wall St · 1d ago
PTC Therapeutics Chief Technical Ops Officer Neil Gregory Almstead disposes of 23,749 common shares worth $1.95 million
PUBT · 2d ago
The Prognosis For PTC Therapeutics
Seeking Alpha · 3d ago
PTC Therapeutics Exec VP, CLO Mark Elliott Boulding disposes of 10,462 common shares worth $823,540
PUBT · 4d ago
Weekly Report: what happened at PTCT last week (0615-0619)?
Weekly Report · 5d ago
PTC Therapeutics Completes Major Convertible Notes Offering
TipRanks · 06/18 22:29
PTC Therapeutics prices USD 550 million zero-coupon convertible notes due 2031
PUBT · 06/18 20:15
More
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Webull offers PTC Therapeutics, Inc. stock information, including NASDAQ: PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.